News >

Update Offers New Insight on Atezolizumab/Bevacizumab Benefit in RCC

Jason Harris
Published: Wednesday, Aug 23, 2017

Michael Atkins, MD

Michael Atkins, MD
The combination of frontline atezolizumab (Tecentriq) and bevacizumab (Avastin) demonstrated superior efficacy compared with sunitinib (Sutent) or atezolizumab monotherapy in patients with advanced renal cell carcinoma (RCC), according to findings from the phase II IMmotion150 study 

The ongoing phase III IMmotion151 trial is comparing frontline atezolizumab/bevacizumab with sunitinib in patients with advanced RCC (NCT02420821).
Atkins MB, McDermott DF, Powles T, et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol. 35, 2017 (suppl; abstr 4505).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication